Welcome to our dedicated page for Kura Oncology SEC filings (Ticker: KURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kura Oncology, Inc. filings document a Nasdaq-listed biopharmaceutical company focused on precision medicines for cancer, including disclosures on KOMZIFTI™ (ziftomenib), acute myeloid leukemia programs, darlifarnib (KO-2806) and collaboration activity with Kyowa Kirin. Form 8-K reports cover financial results, FDA approval and product-launch disclosures, clinical program updates, milestone payments and other material events.
Governance filings include the company’s definitive proxy statement for annual meeting matters, director elections, auditor ratification and executive compensation. Other filings describe amendments to bylaws, the 2023 Inducement Option Plan, nonstatutory stock option grants and the company’s common stock listing on The Nasdaq Global Select Market.
Kura Oncology’s Chief Commercial Officer Brian T. Powl reported routine share sales related to tax withholding on vested restricted stock units. On January 27, 2026, he sold 4,842 and 1,572 shares of common stock at prices of $8.4606 and $8.4607 per share, respectively, as sell-to-cover transactions for RSUs granted on January 2, 2025 and January 2, 2024. Following these sales, he directly owned 183,275 shares of Kura Oncology common stock.
Kura Oncology, Inc. Chief Operating Officer Kathleen Ford reported a small stock sale related to tax withholding. On 01/27/2026, she sold 1,813 shares of common stock at $8.4607 per share in a transaction coded “S.”
The filing explains this was a sell-to-cover for taxes tied to the vesting of a restricted stock unit granted on 01/26/2022. After this transaction, Ford beneficially owned 153,560 shares of Kura Oncology common stock in direct form.
Kura Oncology Chief Medical Officer Mollie Leoni reported routine share sales tied to tax withholding on restricted stock units (RSUs). On January 27, 2026, she sold a total of 8,180 shares of Kura Oncology common stock at $8.4607 per share in four transactions classified as "sell-to-cover" for RSU vesting taxes.
After these sales, Leoni directly beneficially owned 267,274 shares of Kura Oncology common stock, indicating she retains a substantial equity position while satisfying tax obligations from prior RSU awards.
Kura Oncology, Inc. senior vice president of finance and accounting Thomas James Doyle reported several small sales of common stock on January 27, 2026, each at $8.4607 per share. The transactions were sell-to-cover trades for taxes tied to vesting restricted stock units granted between 2022 and 2025.
After these sales, Doyle beneficially owns 145,167 Kura Oncology common shares directly and an additional 500 shares indirectly through his spouse’s 401(k) account, indicating he retains a substantial equity stake in the company following the tax-related transactions.
Kura Oncology, Inc. Chief Scientific Officer Francis Burrows reported a small sale of company stock in connection with tax withholding. On January 27, 2026, he sold 1,311 shares of common stock at $8.4607 per share in a sell-to-cover transaction for taxes tied to the vesting of a restricted stock unit granted on January 26, 2022.
After this transaction, Burrows beneficially owns 32,424 shares of Kura Oncology common stock, held directly.
Kura Oncology Chief Legal Officer Teresa Bair reported routine tax-related stock sales. On 01/27/2026, she sold 4,096, 2,335 and 4,777 shares of Kura Oncology common stock in three separate transactions, each at $8.4607 per share.
All three transactions were disclosed as sell-to-cover trades for taxes due on vesting restricted stock units granted on 02/16/23, 01/02/24 and 01/02/25. Following the last transaction, she directly beneficially owned 226,931 Kura Oncology shares.
A holder of KURA common stock filed a notice of intent to sell shares under Rule 144. The planned sale covers 6,414 shares of common stock with an aggregate market value of $54,326.58, to be executed through Morgan Stanley Smith Barney on 01/27/2026 on NASDAQ. The shares come from restricted stock units acquired from the issuer on the same date in two grants of 4,842 and 1,572 shares.
A shareholder of KURA filed a notice of intent to sell up to 11,208 shares of common stock on or about 01/27/2026 through Morgan Stanley Smith Barney LLC on the NASDAQ market, with an aggregate market value of $94,931.76.
The shares relate to restricted stock units that vested on 01/27/2026 in three blocks of 4,096, 2,335, and 4,777 shares acquired from the issuer. The filing notes that there were 88,309,441 shares of this class outstanding and includes a representation that the seller is not aware of undisclosed material adverse information about the issuer.
Kura Oncology insider plans a small stock sale under Rule 144. A shareholder intends to sell 1,813 shares of Kura Oncology common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $15,356.11.
The filing states that 88,309,441 shares of common stock were outstanding. The shares to be sold were acquired from the issuer as restricted stock units (RSUs) on January 27, 2026, the same date targeted for the sale.
A security holder of KURA has filed a notice of proposed sale of 1,311 shares of common stock under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ, with an aggregate market value of $11,104.17.
The filing states there are 88,309,441 shares of this class outstanding. The seller acquired the 1,311 shares as restricted stock units (RSUs) from the issuer on 01/27/2026. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer.